Results 321 to 330 of about 172,791 (358)

Infliximab for the treatment of psoriasis

Expert Opinion on Biological Therapy, 2006
Psoriasis is a common immune-mediated skin disease producing significant morbidity. Tumour necrosis factor (TNF)-alpha, a pro-inflammatory cytokine, plays a key role in the cutaneous inflammation characteristic of psoriasis. Infliximab is a chimeric monoclonal antibody that specifically binds to TNF-alpha, thereby blocking its biological activity. Data
Kleyn, C. Elise, Griffiths, Christopher E M   +1 more
openaire   +3 more sources

Brodalumab for the treatment of psoriasis

Expert Review of Clinical Immunology, 2016
Psoriasis is a complex disease in which the alteration of the IL-23/Th17 axis appears to be crucial for its pathogenic mechanisms, and anti-IL17 agents are rapidly becoming important therapeutic tools. Brodalumab, a fully human Chinese hamster ovary cell-derived immunoglobulin G2 (IgG2) anti-IL-17RA monoclonal antibody, is currently the most-developed ...
Galluzzo, M, D'Adamio, S, BIANCHI, LUCA, Talamonti, M.   +3 more
openaire   +3 more sources

THE TREATMENT OF PSORIASIS.

JAMA: The Journal of the American Medical Association, 1883
[Read before the Philadelphia Country Medical Society, October 17, 1883.] Psoriasis is one of the commoner skin diseases met with in this country. The statistics of the American Dermatological Association show that it occurs in the proportion of about 6 per cent, in all diseases of the skin encountered.
openaire   +3 more sources

Ustekinumab for the treatment of psoriasis

Expert Review of Clinical Immunology, 2011
Management of psoriasis over the last decade has changed significantly with the introduction of biological therapies. Ustekinumab is a first-in-class biological agent, inhibiting the action of IL-12 and IL-23, and has provided further evidence for the role of Th1 and Th17 lymphocytes in the pathogenesis of psoriasis.
Laws, Philip M., Warren, Richard B.
openaire   +3 more sources

Topical treatment of psoriasis

Expert Opinion on Pharmacotherapy, 2010
The majority of patients with psoriasis can be safely and effectively treated with topical therapy alone, either under the supervision of a family physician or dermatologist. For those requiring systemic agents, topical therapies can provide additional benefit.
Laws, Philip M, Young, Helen S
openaire   +4 more sources

Tofacitinib for the treatment of psoriasis

Expert Opinion on Pharmacotherapy, 2016
The identification of a number of psoriasis-susceptibility genes and a better understanding of the pathogenesis of the intracellular metabolic pathways, have generated new perspectives on psoriasis treatment, in particular new compounds that inhibit certain intracellular proteins involved in the immune response.
Galluzzo, M, D'Adamio, S, Servoli, S, BIANCHI, LUCA, CHIMENTI, SERGIO, Talamonti, M.   +5 more
openaire   +4 more sources

The topical treatment of psoriasis

Clinical and Experimental Dermatology, 2005
Item does not contain ...
openaire   +3 more sources

Photochemotherapy Treatment for Psoriasis

Physical Therapy, 1981
Psoriasis is a disease resulting from accelerated replication and abnormal maturation of epidermal cells.1 It has a 1 to 2 percent prevalence in the United States.1 Currently, therapy is merely suppressive. Conventional treatment for psoriasis is the Goeckerman technique, involving the use of tar and ultraviolet B (UVB) (290–320 nm).2 Classically ...
Richard L. Zuehlke, Donald G Shurr
openaire   +3 more sources

Treatment of Psoriasis with Riboflavin

Archives of Dermatology, 1958
The therapeutic effects of riboflavin in psoriasis have recently been studied by several investigators. Their results are rather varied. Luscombe 1 reported marked improvement in 45% and improvement in 43% of the cases he followed and concluded that this form of therapy was a welcome addition to our armamentarium.
Bencel L. Schiff, Arthur B. Kern
openaire   +3 more sources

Treatment of Psoriasis

The American Journal of Nursing, 1976
C, North, G D, Weinstein
openaire   +2 more sources